Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges
Executive Summary
Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs
You may also be interested in...
Gottlieb Advances, But FDA's Future Seems Increasingly Partisan
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
Cephalon's Double Trouble: DoJ Probes Treanda Marketing, Clinical Trial Data
The inquiry comes three years after the company settled a government investigation of off-label marketing of three other drugs.
Cephalon Is First Company To Release Physician Payments Under Consent Decree
The company, which does not cap its physician payments, paid 937 doctors for consulting and speaking services in 2009; its top-paid physician earned $149,900.